1000/1000
Hot
Most Recent
Hydrodynamics-based gene delivery (HGD) is an efficient method for transfecting hepatocytes with plasmid DNA in vivo, but always associated with transient and non-tissue-specific expression of a gene of interest (GOI). piggyBac (PB) transposon system enables chromosomal integration of GOIs, and as a result long-term expression of GOI is possible. In this study, we combined these two technologies to enable liver-specific expression of GOI for a long time. Mice are first subjected to HGD with a PB transposase expression plasmid and a PB transposon containing the GOIs placed downstream of the stopper sequence flanked by loxP. When the same mice are next subjected to HGD with a liver-directed Cre expression plasmid, Cre-mediated excision of loxP-flanked stopper sequence in the chromosomally integrated transposon and subsequent expression of GOIs occur. This Cre/loxP-based regulatable gene switching system together with combined used of HGD and PB will be useful for in situ manipulation of hepatocyte genome in non-transgenic animals.
In animal experiment, tail-vein injection of nucleic acids (NAs) (as exemplified by plasmid DNA) is simple and convenient for NAs delivery into a living organism. HGD is performed by a hydrodynamic force generated by a pressurized injection of a large volume of DNA solution into the blood vessel. As a result, the force leads to generation of transient pores in the hepatocyte cell membrane. While the pores exist, NAs present in the solution enter the hepatocytes and are trapped in the cells; part of them migrates to the nucleus, where they facilitate targeted gene expression [1][2]. Unfortunately, gene expression in the liver is generally transient, because the NAs introduced by the HGD is often refractory to chromosomal integration into liver genome [3]. Furthermore, other organs (such as lung and kidney) besides the liver are often transfected, since it is mediated by tail-vein injection [4].
The PB system derived from the cabbage looper moth Trichoplusia ni [5] is a one of the transposon–transposase system for efficient genetic modification of mammalian cells [6]. The PB transposase recognizes transposon-specific inverted terminal repeat sequences (ITRs) located on both ends of the transposon vector and efficiently integrates transgenes into the host genome [7]. However, the PB-mediated gene delivery system results in random integration of transgenes, leading to occasional transgene silencing, insertional mutagenesis, and positional variegation, probably as a result of transgene silencing [8][9]. The PB-based gene delivery has been reported to confer efficient chromosomal integration of GOIs in various types of in vitro cultured cell [10][11], generation of transgenic (Tg) mice [10], gene discovery via insertional mutagenesis [12], and production of inducible pluripotent stem (iPS) cells [13]. Furthermore, in vivo long-term gene expression of GOI after HGD using PB-related vectors has been reported [14].
Although HGD is an efficient method enabling gene transfer into the liver more preferentially, it does not guarantee liver-specific gene expression. If a researcher wants to express a GOI only in the liver using HGD, the use of a liver-specific promoter for driving GOI expression is a promising approach. However, most liver-specific promoters identified to date have weaker promoter activity than the widely used universal promoter such as SV40 early or cytomegalovirus (CMV) promoter, which often makes it difficult to use liver-specific promoters to achieve stronger expression of a GOI.
There are several ways to enhance the activity of a tissue-specific but transcriptionally weak promoter [15][16][17]. For example, Nettelbeck et al. [18] provided a two-step amplification (TSTA) system, by which strong expression of GOI was induced by a strong promoter that had been activated through binding to the transcriptional activator produced from a weak promoter. We also established a similar two-step approach for enhancing the expression of a GOI by employing the Cre/loxP-based gene switching system [19]. By using this system, strong and liver-specific expression of a GOI could be successfully achieved even when a transcriptionally weak but liver-specific promoter was employed.
To examine whether PB transposons introduced into murine liver through HGD can guarantee the sustained expression of a GOI [enhanced green fluorescent protein (EGFP) cDNA in this case], mice were intravenously injected with a solution containing two PB-related vectors and a non-PB ptdTomato vector using HGD. The fluorescence of EGFP derived from PB vector was still detected on the liver samples isolated 56 days after HGD [20]. In contrast, the fluorescence of tdTomato derived from non-PB vector was undetectable on the samples isolated 28 days or more after HGD [20]. These results indicate that PB-based gene delivery is more effective for sustained gene expression of a GOI in murine liver.
To our knowledge, no reports of the both achievement of long-term and tissue-specific expression of a GOI in vivo have been published. To achieve this, we used our past established Cre/loxP-based gene switching system [19], which employed both viral-derived universal promoter and liver-specific promoter.
Using this system, we attempted to express a protein of diphtheria toxin-A chain (DT-A) in mouse liver in a conditional manner. DT-A is known to be a potent protein leading to cell death through the inactivation of peptide elongation factor [21]. Mice were first subjected to HGD with a PB transposase expression plasmid and a PB transposon containing the GOIs (DT-A gene in this case) placed downstream of the stopper sequence flanked by loxP. When the same mice were next subjected to HGD with a liver-directed Cre expression plasmid (pTR/NCre), Cre-mediated excision of loxP-flanked stopper sequence in the chromosomally integrated transposon and subsequent expression of DT-A gene occurred. Due to conditional expression of DT-A gene in mouse liver, hepatocyte death frequently occurred and as a result, liver disease was induced (Exp. gr. in Figure 1).
Figure 1. HGD and PB transposon system enable the creation of disease models for liver dysfunction. When serum biochemistry profiles were assessed using blood samples, elevated levels of aspartate transaminase (AST) and alanine transaminase (ALT) in the experimental group were identified compared with those in control groups-1 (injection of pTR/LacZ) and -2 (intact). The level of significance set at p < 0.05 marked with an asterisk. Values are expressed as mean ± standard deviation among three mice tested for each group.
Using PB and HGD, we successfully achieved the sustained expression of a GOI in murine liver [20]. When Cre/loxP-based gene switching is combined with this PB-based HGD system, it is theoretically possible to induce liver-specific expression of GOI at any time the researcher wants. When we applied these technologies to produce liver disease model mice as proof-of-principle experiment, the resultant mice exhibited altered biochemical parameters and pathological abnormality. This present gene-based technology should also be useful for establishing an in situ manipulation system to assess liver function without the need to produce Tg animals.